首页> Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases> Emergence of dalbavancin non-susceptible, vancomycin-intermediate Staphylococcus aureus (VISA) after treatment of MRSA central line-associated bloodstream infection with a dalbavancin- and vancomycin-containing regimen.

Emergence of dalbavancin non-susceptible, vancomycin-intermediate Staphylococcus aureus (VISA) after treatment of MRSA central line-associated bloodstream infection with a dalbavancin- and vancomycin-containing regimen.

导出原文传递

翻译打印收藏纠错

第一作者： B J,Werth

第一单位： Department of Pharmacy, University of Washington School of Pharmacy, Seattle, WA, USA.

作者： B J,Werth ^[1] ; R,Jain ^[1] ; A,Hahn ^[2] ; L,Cummings ^[3] ; T,Weaver ^[3] ; A,Waalkes ^[3] ; D,Sengupta ^[3] ; S J,Salipante ^[3] ; R M,Rakita ^[2] ; S M,Butler-Wu ^[4]

作者单位： Department of Pharmacy, University of Washington School of Pharmacy, Seattle, WA, USA. ^[1] Division of Allergy and Infectious Diseases, Department of Medicine, University of Washington, Seattle, WA, USA. ^[2] Department of Laboratory Medicine, University of Washington, Seattle, WA, USA. ^[3] Department of Laboratory Medicine, University of Washington, Seattle, WA, USA. Electronic address: butlerwu@usc.edu. ^[4]

关键词 CLABSI Cross-resistance Dalbavancin Glycopeptide resistance Lipoglycopeptide